CGTLive’s Weekly Rewind – August 19, 2022

Article

Review top news and interview highlights from the week ending August 19, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Alexis Thompson, MD, MPH, on Beti-Cel's Approval in β-Thalassemia

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed beti-cel's approval.

2. FDA Approves Beti-Cel Gene Therapy for β-Thalassemia

ZYNTEGLO previously received a unanimous, favorable, vote from the FDA advisory committee.

3. Merit Cudkowicz, MD, on Evaluating Mesenchymal Cell Therapy for ALS

BrainStorm Cell Therapeutics has decided to submit a BLA for NurOwn in ALS following an erratum to a phase 3 trial.

4. Tisa-Cel Associated With Improved Outcomes at Higher Doses

Higher doses were associated with improved overall survival, event-free survival, and relapse-free survival.

5. Homology Trades in Gene Delivery for Gene Editing to Treat Phenylketonuria

The pheEDIT clinical trial initiated in June 2022.

Related Videos
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
© 2024 MJH Life Sciences

All rights reserved.